Salarius Pharmaceuticals, Inc.

Clinical-stage biopharma developing targeted protein therapies for cancer and viral diseases.

SLRX | NDAQ

Overview

Corporate Details

ISIN(s):: US79400X4043 (+1 more)
LEI:
Country:: United States of America
Address:: 2450 HOLCOMBE BLVD, 77021 HOUSTON
Website:: https://salariuspharma.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with cancer and other diseases with high unmet medical needs. The company's technology aims to correct the dysregulated gene expression that drives disease progression. Its pipeline is built on two primary drug classes: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials for solid and hematologic cancers like leukemias and lymphomas. The company's TPD candidate, SP-3164, is in IND-enabling studies. Following a merger with Decoy Therapeutics, Salarius is also advancing peptide therapeutics for cancer and respiratory viruses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Salarius Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Salarius Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Salarius Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
RELMADA THERAPEUTICS, INC. A clinical-stage biotech developing novel therapies for CNS diseases and oncology.	United States of America	RLMD
Renascience Inc. Develops innovative drugs and AI-powered medical devices for aging and hereditary diseases.	Japan	4889
Rentracks CO.,LTD. A pay-per-performance ad network with a closed ASP and comprehensive web consulting services.	Japan	6045
Replimune Group, Inc. Clinical-stage biotech developing oncolytic immunotherapies to treat a broad range of cancers.	United States of America	REPL
ReproCELL Incorporated Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.	Japan	4978
RESEARCH FRONTIERS INC Develops and licenses smart glass tech for instant light, UV, and heat control.	United States of America	REFR
Resolute Holdings Management, Inc. Asset management firm acquiring and operationally enhancing companies for long-term growth.	United States of America	RHLD
RIBOMIC Inc. Develops RNA aptamer therapeutics for ophthalmology, pain, fibrosis, and other unmet medical needs.	Japan	4591
Rise Consulting Group, Inc. Execution-focused consulting for strategy and digital transformation, specializing in JP-CN markets.	Japan	9168
ROQUEFORT THERAPEUTICS PLC Developing first-in-class, pre-clinical medicines for hard-to-treat cancers.	United Kingdom	ROQ